Updated treatment guidelines for drug-resistant TB: how safe are clofazimine-based regimens?

E Pontali, M Raviglione
{"title":"Updated treatment guidelines for drug-resistant TB: how safe are clofazimine-based regimens?","authors":"E Pontali, M Raviglione","doi":"10.5588/ijtldopen.24.0490","DOIUrl":null,"url":null,"abstract":"<p><p>In June 2024, WHO released 'Key updates to the treatment of drug-resistant tuberculosis: rapid communication', after the preliminary publication of results from two clinical trials: 'BEAT-Tuberculosis' and 'endTB'. All proposed regimens include clofazimine (Cfz). However, a recent paper has reported a high incidence of QTc prolongation among patients receiving Cfz-based treatment for multidrug-resistant TB in Taiwan. Here, we discuss the cardiac safety of Cfz and the role of active drug safety monitoring at the programme level in collecting information on this issue.</p>","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"1 11","pages":"486-489"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558786/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJTLD open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5588/ijtldopen.24.0490","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

In June 2024, WHO released 'Key updates to the treatment of drug-resistant tuberculosis: rapid communication', after the preliminary publication of results from two clinical trials: 'BEAT-Tuberculosis' and 'endTB'. All proposed regimens include clofazimine (Cfz). However, a recent paper has reported a high incidence of QTc prolongation among patients receiving Cfz-based treatment for multidrug-resistant TB in Taiwan. Here, we discuss the cardiac safety of Cfz and the role of active drug safety monitoring at the programme level in collecting information on this issue.

耐药性结核病最新治疗指南:基于氯唑明的治疗方案有多安全?
2024 年 6 月,在 "BEAT-Tuberculosis "和 "endTB "两项临床试验的初步结果公布后,世卫组织发布了 "耐药结核病治疗的关键更新:快速交流"。所有建议的治疗方案都包括氯唑明(Cfz)。然而,最近有一篇论文报道,在台湾,接受氯法齐明治疗耐多药结核病的患者中,QTc 延长的发生率很高。在此,我们讨论了氯羟嗪的心脏安全性以及在计划层面上积极开展药物安全性监测在收集相关信息方面所起的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信